Department of Hematology, National Center for Global Health and Medicine, Tokyo, Japan.
Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan.
J Infect Chemother. 2021 Oct;27(10):1498-1503. doi: 10.1016/j.jiac.2021.07.016. Epub 2021 Jul 24.
Many articles have reported that the coronavirus disease 2019 (COVID-19) causes coagulation abnormalities and pulmonary thrombosis, contributing to a poorer prognosis. The study aimed to evaluate whether pre-admission anticoagulation and antiplatelet therapy prevented severe COVID-19 illness or not.
We conducted a study to determine whether taking antiplatelet or anticoagulation agents before admission affected the severity on admission using a large nationwide cohort of hospitalized COVID-19 patients in Japan. We analyzed a large nationwide cohort of hospitalized COVID-19 patients in Japan from February 9 to July 31, 2020.
A total of 4265 patients from 342 facilities in Japan were included. Their use was associated with a slight reduction in the disease severity on admission in a propensity score-matched analysis which controlled for underlying diseases. However, this difference was not statistically significant.
许多文章报道称，2019 年冠状病毒病（COVID-19）可引起凝血异常和肺血栓形成，导致预后较差。本研究旨在评估入院前抗凝和抗血小板治疗是否可预防重症 COVID-19 疾病。
我们进行了一项研究，以确定在日本住院 COVID-19 患者的大型全国队列中，入院前使用抗血小板或抗凝药物是否会影响入院时的严重程度。我们分析了 2020 年 2 月 9 日至 7 月 31 日期间来自日本 342 家机构的住院 COVID-19 患者的大型全国队列。
共纳入日本 342 家机构的 4265 例患者。在倾向评分匹配分析中，与未使用这些药物的患者相比，使用这些药物的患者入院时的疾病严重程度略有降低，该分析控制了潜在疾病的影响。但是，这一差异无统计学意义。
